209 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
German language Session
Q&A Modul
SCIENTIFIC PROGRAMME
201
S-304
Symposium
15:15– 16:45
|
Hall Helsinki 1
TOPIC 20:
Prevention and health promotion
Stress and resilience in current migrations
›
WPA Section: Transcultural Psychiatry
Chairs:
Joseba Achotegui, Spain
Rachid Bennegadi, France
001
Incorporating resilience in the treatment of
asylum seekers and refugees
Cornelis J. Kees Laban, The Netherlands
002
Resilience and depression in immigrants
Jose López, Peru
003
Resilience and post-traumatic stress disorders
in immigrants
Rachid Bennegadi, France
004
Stress and resilience in the Ulysses Syndrome
(Chronic and multiple stress in immigrants)
Joseba Achotegui, Spain
S-305
Symposium
15:15– 16:45
|
Hall Paris 1
TOPIC 26:
Ethics and philosophy
The proposed WPA code of ethics – history, dilemmas
and future implementation
Chairs:
Marianne C. Kastrup, Denmark
Sam Tyano, Israel
001
Historical overview of the WPA code of ethics
Paul Appelbaum, USA
002
The UN Convention on the Rights of Persons
with Disabilities unintended consequences
Michael Jan Wise, United Kingdom
003
Educational implications
Cecile Hanon, France
004
Ethical dilemmas: where principles meet reality
in clinical practice
Julian Beezhold, United Kingdom
S-306
Symposium
15:15– 16:45
|
Hall Paris 2
TOPIC 18:
Pharmacotherapy
The German national plan of action for people with
rare diseases and its relevance for the off-label use
of drugs – symposium of the federal institute for
drugs and medical devices
Chairs:
Jürgen Fritze, Germany
Karl Broich, Germany
001
The national action league for people with rare
diseases
Theda Wessel, Germany
002
Off-label use – methodology and overview of
the findings
Jürgen Fritze, Germany
003
Legal and research implications of the findings in
psychostimulants, antidepressants and neuroleptics
Claudia Riedel, Germany
004
Legal and research implications of the findings
in antidementives, anticonvulsants and immunosup-
pressants
Peggy Beinlich, Germany
S-307
Symposium
15:15– 16:45
|
Hall Berlin 1
TOPIC 2:
Mental disorders due to psychotropic
substances, behavioural addictions
Withdrawal from psychotropics
Chairs:
Peter Lehmann, Germany
Andreas Heinz, Germany
001
International institute for psychiatric drug
withdrawal
Peter C. Gøtzsche, Denmark
002
Do antidepressants cause dependence? A com-
parison to benzodiazepines with special regard to
withdrawal reactions
Tom Bschor, Germany
003
The withdrawal of neuroleptics: When to do
so? How? When not to do so? What then?
Volkmar Aderhold, Germany
004
Start low, go slow – bridging the divide be-
tween the lack of clinical research on safe psychi-
atric drug withdrawal protocols and the growing
evidence base of successful tapering methodologies
by users of psychiatric drugs
Laura Delano, USA